Literature DB >> 29603390

Commercial scale production of RvD4 opens the resolving door to new research.

Matthew L Edin1, Darryl C Zeldin1.   

Abstract

Entities:  

Year:  2018        PMID： 29603390      PMCID： PMC6165702          DOI： 10.1002/JLB.3CE0118-032R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


× No keyword cloud information.
  9 in total

1.  Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways.

Authors:  Senad Divanovic; Jesmond Dalli; Lucia F Jorge-Nebert; Christopher L Karp; Charles N Serhan; Daniel W Nebert; Leah M Flick; Marina Gálvez-Peralta; Nicholas D Boespflug; Traci E Stankiewicz; Jonathan M Fitzgerald; Maheshika Somarathna
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

2.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors.

Authors:  Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang; Stephanie Yacoubian; Chih-Hao Lee; Rong Yang; Nicos A Petasis; Charles N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 3.  Novel anti-inflammatory--pro-resolving mediators and their receptors.

Authors:  Charles N Serhan; Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

4.  15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.

Authors:  Ido Wolf; James O'Kelly; Tamar Rubinek; Min Tong; Anh Nguyen; Bryan T Lin; Hsin-Hsiung Tai; Beth Y Karlan; H Phillip Koeffler
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

5.  Structural insights into Resolvin D4 actions and further metabolites via a new total organic synthesis and validation.

Authors:  Jeremy W Winkler; Stephania Libreros; Xavier De La Rosa; Brian E Sansbury; Paul C Norris; Nan Chiang; David Fichtner; Gregory S Keyes; Nicholas Wourms; Matthew Spite; Charles N Serhan
Journal:  J Leukoc Biol       Date:  2018-01-29       Impact factor: 4.962

Review 6.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

7.  Resolvin Infectious Inflammation by Targeting the Host Response.

Authors:  Craig R Lee; Darryl C Zeldin
Journal:  N Engl J Med       Date:  2015-11-26       Impact factor: 91.245

Review 8.  DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation.

Authors:  Melody G Duvall; Bruce D Levy
Journal:  Eur J Pharmacol       Date:  2015-11-03       Impact factor: 4.432

Review 9.  Specialized pro-resolving mediators: endogenous regulators of infection and inflammation.

Authors:  Maria C Basil; Bruce D Levy
Journal:  Nat Rev Immunol       Date:  2015-12-21       Impact factor: 53.106
  9 in total
  2 in total

Review 1.  E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.

Authors:  Charles N Serhan; Stephania Libreros; Robert Nshimiyimana
Journal:  Semin Immunol       Date:  2022-02-16       Impact factor: 11.130

Review 2.  Specialized Pro-Resolving Mediators Mitigate Cancer-Related Inflammation: Role of Tumor-Associated Macrophages and Therapeutic Opportunities.

Authors:  Margot Lavy; Vanessa Gauttier; Nicolas Poirier; Sophie Barillé-Nion; Christophe Blanquart
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.